Hematologic Cancers

Uncertainties Surround Optimal Dosing of Cytarabine in AML

By

Susan Moench, PhD, PA-C

Publish Date January 14, 2021

This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).

PARP Inhibition Associated With Increased Risk for Secondary MDS, AML

By

Christina Bennett, MS

Publish Date January 13, 2021

Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.

Study Finds Low Adherence to Lenalidomide Therapy in Multiple Myeloma

By

Christina Bennett, MS

Publish Date January 13, 2021

Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.

Pegylated Interferon Controlled Extreme Thrombocytosis, Well-Tolerated in Younger Patients With MPN

By

Jessica Nye, PhD

Publish Date January 12, 2021

A review of 13 cases of MPN in younger patients sought to determine whether pegylated interferon, used to treat adult patients with these diseases, was appropriate for patients younger than 21.

Improvements Seen in Allogeneic Stem Cell Transplantation-Related Mortality

By

Jonathan Goodman, MPhil

Publish Date January 8, 2021

Experts assessed mortality rates linked to allogeneic stem cell transplantation in the past 40 years using data from the European Society for Blood and Marrow Transplantation registry.